6,9-二氧代-11alpha,15S-二羟基-前列腺-13E-烯-1-酸 | 67786-53-2

• 物质功能分类: 有机原料 - 酮类化合物
• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 中文名称: 6,9-二氧代-11alpha,15S-二羟基-前列腺-13E-烯-1-酸
• 中文别名: 6-酮前列腺素E1
• 英文名称: 6-keto prostaglandin E1
• 英文别名: 6-ketoprostaglandin E1；7-[(1R,2R,3R)-3-hydroxy-2-[(E,3S)-3-hydroxyoct-1-enyl]-5-oxocyclopentyl]-6-oxoheptanoic acid
• CAS: 67786-53-2
• 化学式: C₂₀H₃₂O₆
• 分子量: 368.47
• InChiKey: ROUDCKODIMKLNO-CTBSXBMHSA-N

物化性质

• 溶解度：
  乙醇：>50 mg/ml（来自 PGE1）； DMF：>100 mg/ml（来自 PGE1）； DMSO：>50 mg/ml（来自 PGE1）； PBS pH 7.2：>1.6 mg/ml（来自 PGE1）
• 物理描述：
  Solid

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  26
• 可旋转键数：
  13
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.75
• 拓扑面积：
  112
• 氢给体数：
  3
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  4-(9-腺嘌呤)溴苯乙酮 、 6,9-二氧代-11alpha,15S-二羟基-前列腺-13E-烯-1-酸 、 N,N-二异丙基乙胺 生成 [4-[2-[7-[(1R,2R,3R)-3-hydroxy-2-[(E,3S)-3-hydroxyoct-1-enyl]-5-oxocyclopentyl]-6-oxoheptanoyl]oxyacetyl]phenyl] anthracene-9-carboxylate
  参考文献：
  名称：

  SALARI, HASSAN;YEUNG, MOIRA;DOUGLAS, SCOTT;MOROZOWICH, WALTER, ANAL. BIOCHEM., 165,(1987) N 1, 220-229

  摘要：

  DOI：
• 作为产物：
  描述：

  (1E,3S)-1-iodo-3-(tert-butyldimethylsiloxy)-1-octene 在 氟化氢吡啶 作用下， 以 乙腈 为溶剂， 反应 21.0h， 生成 6,9-二氧代-11alpha,15S-二羟基-前列腺-13E-烯-1-酸
  参考文献：
  名称：

  短的合成的6- oxoprostaglandinë 1和6-oxoprostaglandin˚F 1α

  摘要：

  在一个锅中，通过（ω ）-4-丁基二甲基甲硅烷氧基-2-环戊烯酮，通过带有ω侧链单元的有机铜共轭加成，用6-甲氧基羰基-2-硝基己酮捕获所得的烯醇化物，在一个锅中合成了6-氧杂戊二烯酸E 1甲酯。-1-烯，并用三氯化钛（III）水溶液处理。通过猪肝酯酶完成甲酯的水解。6- Oxoprostaglandin˚F 1α，由得到的6- nitroprostaglandinë 1甲酯在四个步骤。

  DOI：

  10.1016/s0040-4039(01)91266-3

文献信息

• EPOTHILONE DERIVATIVES, METHOD FOR PRODUCING SAME AND THEIR PHARMACEUTICAL USE
  申请人：——

  公开号：US20030144523A1

  公开（公告）日：2003-07-31

  This invention relates to the new epothilone derivatives of general formula I, 1 in which substituents Y, Z R 2a , R 2b , R 3 , R 4a , R 4b , D—E, R 5 , R 6 , R 7 , R 8 and X have the meanings that are indicated in more detail in the description. The new compounds interact with tubulin by stabilizing microtubuli that are formed. They are able to influence the cell-splitting in a phase-specific manner and are suitable for treating malignant tumors, for example, ovarian, stomach, colon, adeno-, breast, lung, head and neck carcinomas, malignant melanomas, acute lymphocytic and myelocytic leukemia. In addition, they are suitable for anti-angiogenesis therapy as well as for treatment of chronic inflammatory diseases (psoriasis, arthritis). To avoid uncontrolled proliferation of cells and for better compatibility of medical implants, they can be applied or introduced into polymer materials. The compounds according to the invention can be used alone or to achieve additive or synergistic actions in combination with other principles and classes of substances that can be used in tumor therapy.

  本发明涉及具有通式I的新埃波替隆衍生物，其中取代基Y、Z、R2a、R2b、R3、R4a、R4b、D—E、R5、R6、R7、R8和X的含义在描述中更详细地指出。这些新化合物通过与微管蛋白的相互作用来稳定形成的微管。它们能够以阶段特异性的方式影响细胞分裂，并适用于治疗恶性肿瘤，例如卵巢、胃、结肠、腺体、乳腺、肺、头颈癌、恶性黑色素瘤、急性淋巴细胞和骨髓细胞白血病。此外，它们还适用于抗血管生成治疗以及治疗慢性炎性疾病（银屑病、关节炎）。为了避免细胞的不受控制的增殖以及提高医疗植入物的相容性，它们可以应用于或引入到聚合物材料中。根据发明的化合物可以单独使用，也可以与其他可用于肿瘤治疗的原理和物质类别结合使用，以实现相加或协同作用。
• Novel epothilone derivatives, method for the preparation thereof and their pharmaceutical use
  申请人：——

  公开号：US20040058969A1

  公开（公告）日：2004-03-25

  The invention relates to novel epothilone derivatives of general formula (1), wherein R 5 represents a halogen atom or a cyano group and the other substituents have the meanings as cited in the description. The novel compounds interact with tubulin by stabilizing formed microtubules. They are capable of influencing the cell division in a phase-specific manner and are well-suited for the treatment of malignant tumors, for example, ovarian, stomach, colon, adeno, breast, lung, head and neck carcinomas, malignant melanoma, acute lymphocytic and myelocytic leukemia. In addition, they are well-suited for anti-angiogenesis therapy and for the treatment of chronic inflammable medical disorders (psoriasis, arthritis). In order to prevent uncontrolled cell growths as well as to improve the compatibility of medical implants, the inventive epothilone derivatives can be applied to or introduced into polymeric materials. The inventive compounds can be used alone or in order to obtain additive or synergistic effects, in conjunction with additional principles and substance classes that can be used in tumor therapy. 1

  本发明涉及一类通式（1）的新埃博霉素衍生物，其中R 5 代表卤素原子或氰基，其他取代基的含义如描述中引用。这些新颖化合物通过与微管蛋白作用稳定形成的微管。它们能够以特定阶段的方式影响细胞分裂，非常适合治疗恶性肿瘤，例如卵巢癌、胃癌、结肠癌、腺癌、乳腺癌、肺癌、头颈癌、恶性黑色素瘤、急性淋巴细胞和骨髓细胞白血病。此外，它们还非常适合用于抗血管生成治疗和慢性炎症性医疗疾病（银屑病、关节炎）的治疗。为了防止不受控制的细胞生长以及提高医疗植入物的相容性，本发明的埃博霉素衍生物可以施加或引入到聚合物材料中。本发明的化合物可以单独使用，或者为了获得添加剂或协同效应，与肿瘤治疗中可用的其他原理和物质类别联合使用。 1
• 6-Alkenyl-, 6-alkinyl- and 6-epoxy-epothilone derivatives, process for their production, and their use in pharmaceutical preparations
  申请人：Klar Ulrich

  公开号：US20050113429A1

  公开（公告）日：2005-05-26

  This invention describes the new 6-alkenyl- and 6-alkinyl-epothilone derivatives of general formula (I) in which R 1a , R 1b , R 2b , R 3a , R 3b , R 4 , R 5 , R 6 , R 7 , A, Y, D, E, G, Y and Z have the meanings that are indicated in the description. The new compounds interact with tubulin by stabilizing microtubuli that are formed. They are able to influence the cell-splitting in a phase-specific manner and thus find use in treating diseases or conditions associated with the need for cell growth, division and/or proliferation. Thus the compounds are suitable for treating malignant tumors, for example, ovarian, stomach, colon, adeno-, breast, lung, head and neck carcinomas, malignant melanoma, acute lymphocytic and myelocytic leukemia. In addition, they are suitable for anti-angiogenesis therapy as well as for treatment of chronic inflammatory diseases (such as psoriasis, arthritis). Methods of use and preparation of the compounds are also described.

  该发明描述了通式(I)中的新6-烯基-和6-炔基-epothilone衍生物，其中R1a、R1b、R2b、R3a、R3b、R4、R5、R6、R7、A、Y、D、E、G、Y和Z具有说明中指示的含义。这些新化合物通过稳定形成的微管蛋白质与微管结合。它们能够以特定阶段的方式影响细胞分裂，因此可用于治疗与细胞生长、分裂和/或增殖需求相关的疾病或状况。因此，这些化合物适用于治疗恶性肿瘤，例如卵巢、胃、结肠、腺癌、乳腺、肺、头颈癌、恶性黑色素瘤、急性淋巴细胞和骨髓性白血病。此外，它们也适用于抗血管生成治疗以及慢性炎症性疾病的治疗（如牛皮癣、关节炎）。还描述了这些化合物的使用方法和制备方法。
• 6-Alkenyl -, 6-alkinyl- and 6-epoxy-epothilone derivatives, process for their production, and their use in pharmaceutical preparations
  申请人：Klar Ulrich

  公开号：US20060046997A1

  公开（公告）日：2006-03-02

  This invention describes the new 6-alkenyl- and 6-alkinyl-epothilone derivatives of general formula (I) in which R 1a , R 1b , R 2a , R 3a , R 3b , R 4 , R 5 , R 6 , R 7 , A, Y, D, E, G, Y and Z have the meanings that are indicated in the description. The new compounds interact with tubulin by stabilizing microtubuli that are formed. They are able to influence the cell-splitting in a phase-specific manner and thus find use in treating diseases or conditions associated with the need for cell growth, division and/or proliferation. Thus the compounds are suitable for treating malignant tumors, for example, ovarian, stomach, colon, adeno-, breast, lung, head and neck carcinomas, malignant melanoma, acute lymphocytic and myelocytic leukemia. In addition, they are suitable for anti-angiogenesis therapy as well as for treatment of chronic inflammatory diseases (such as psoriasis, arthritis). Methods of use and preparation of the compounds are also described.

  该发明描述了新的6-烯基和6-炔基-依托酮衍生物，其一般式为（I），其中R1a、R1b、R2a、R3a、R3b、R4、R5、R6、R7、A、Y、D、E、G、Y和Z的含义如描述中所示。这些新化合物通过稳定形成的微管蛋白质与微管相互作用。它们能够以特定于阶段的方式影响细胞分裂，因此可用于治疗与细胞生长、分裂和/或增殖需求相关的疾病或症状。因此，这些化合物适用于治疗恶性肿瘤，例如卵巢、胃、结肠、腺癌、乳腺癌、肺癌、头颈癌、恶性黑色素瘤、急性淋巴细胞白血病和骨髓性白血病。此外，它们也适用于抗血管生成治疗以及慢性炎症性疾病（如牛皮癣、关节炎）的治疗。该文还描述了这些化合物的使用方法和制备方法。
• Nitro-olefin trapping reaction of enolates generated by conjugate addition reaction: short syntheses of PGE1, 6-Oxo-PGE1, 6-Oxo-PGF1α, and PGI2
  作者：Toshio Tanaka、Atsuo Hazato、Kiyoshi Bannai、Noriaki Okamura、Satoshi Sugiura、Kenji Manabe、Takeshi Toru、Seizi Kurozumi、Masaaki Suzuki、Toshio Kawagishi、Ryoji Noyori

  DOI：10.1016/s0040-4020(01)90018-3

  日期：1987.1

  in situ generated by conjugate addition of organocopper reagents to the chiral oxygenated cyclopentenone synthon, R-4, gives the three-component coupling products in a regiospecific manner. The intermediary nitronate anion 17 is further transformed into the nitro compound or 6-oxo-PGE1 (19) in a single pot. This coupling reaction is applicable to syntheses of naturally occurring prostaglandins such

  通过将有机铜试剂共轭添加到手性含氧环戊烯酮合成子R-4中，原位生成的烯醇化物被硝基烯烃捕获，从而以区域特异性方式生成三组分偶联产物。在单个罐中将中间体亚硝酸根阴离子17进一步转化为硝基化合物或6-氧代-PGE 1（19）。该偶联反应是适用于天然存在的前列腺素如PGE的合成1，6-氧代PGF 1α，和PGI 2。